glp-1 agonists tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis TrimRX | GLP-1 vs GIP:
Description
For example, merely switching from one dose per week (q1wk) to one dose every two weeks (q2wk) maintains roughly 75% of the weight loss
I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance)
Safe, drug-free, non-GMO, USA-made
GLP-1 RAs have gained attention for treating obesity and type 2 diabetes (T2DM), largely due to their ability to reduce gastric motility
ORLANDO, Fla
